PGEN News and Press, Precigen Inc. From 12/27/22

--News Direct-- Acute myeloid leukemia (AML) is among the most common types of leukemia in adults. The term leukemia refers to cancers of the bone marrow and blood cells. Doctors refer to AML as “acute” because the condition is known to progress rapidly. The five-yea...

Precigen to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire GERMANTOWN, Md. , Dec. 19, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapi...

Precigen, Inc. ( NASDAQ: PGEN ), a biotech focused on gene and cell therapies, has announced Phase 1 data from its Phase 1/1b clinical study for its autologous CAR-T therapy PRGN-3006 in patients with relapsed or refractory acute myeloid leukemia (AML) and higher risk myelodysplastic synd...

Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients PR Newswire – Single infusion of UltraCAR-T cells with or without ly...

Precigen ( NASDAQ: PGEN ) stock rose ~16% on Thursday after Q3 results beat estimates. Net income was $87.38M, compared to net loss of -$29.76M in Q3 2021. Total revenues grew +401.71% Y/Y to $16.72M. Collaboration and licensing revenues increased to $1...

Precigen, Inc. (PGEN) Q3 2022 Earnings Conference Call November 09, 2022 04:30 PM ET Company Participants Steve Harasym - Vice President, Investor Relations Helen Sabzevari - President & Chief Executive Officer Harry Thomasian - Chief Financial Officer ...

Precigen press release ( NASDAQ: PGEN ): Q3 GAAP EPS of -$0.04 beats by $0.10 . Revenue of $16.72M (+402.1% Y/Y) beats by $14M . Cash, cash equivalents, short-term investments and restricted cash totaled $153.8M as of September 30, 2022. For further detai...

Precigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs PR Newswire – Company will host virtual R&D event in early January 2023 , timed to coincide with the 41 st Annual JP Morgan Healthcare Conference , to sho...

Precigen to Announce Third Quarter 2022 Financial Results on November 9th PR Newswire GERMANTOWN, Md. , Nov. 2, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell...

Summary During the third quarter of 2022, the Miller Opportunity Equity strategy generated a total return of -4.62% net of fees. Using a three-factor performance attribution model, allocation, and selection effects contributed to the strategy’s outperformance which was part...